Vitamin D-mediated hypercalcemia in multicentric Castleman’s disease

详细信息    查看全文

• 作者：Ken-ichiro Tanaka ; Ippei Kanazawa ; Hitomi Miyake…
• 关键词：Hypercalcemia ; Castleman disease ; Vitamin D ; 25 ; Hydroxyvitamin D 1 ; alpha ; hydroxylase ; Prednisolone
• 刊名：Journal of Bone and Mineral Metabolism
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：35
• 期：1
• 页码：122-125
• 全文大小：
• 刊物类别：Medicine
• 刊物主题：Metabolic Diseases; Orthopedics;
• 出版者：Springer Japan
• ISSN：1435-5604
• 卷排序：35

文摘

Multicentric Castleman’s disease (MCD) is a rare lymphoproliferative disorder, which represents various symptoms caused by the hyperproduction of interleukin-6 (IL-6). However, case studies of MCD accompanied by hypercalcemia have rarely been reported thus far. A 78-year-old male had generalized fatigue, and his laboratory data revealed elevated serum calcium (Ca) and 1,25-dihydroxyvitamin D [1,25(OH)₂D] levels (11.5 mg/dl and 80 pg/ml, respectively), while the serum intact parathyroid hormone level was low (4 pg/ml). Computed tomography showed multicentric lymphadenopathy. The serum IL-6 level was elevated (20.7 pg/ml), and pathological examination of a supraclavicular lymph node specimen led us to diagnose MCD. Moreover, immunostaining analysis showed that vitamin D-activating enzyme 25-hydroxyvitamin D 1-alpha-hydroxylase was expressed in lymph node macrophages. Prednisolone treatment improved the hypercalcemia and decreased the levels of 1,25(OH)₂D and IL-6. We first reported a case of vitamin D-mediated hypercalcemia in MCD.